Physician profile
Muhammad A Saleemi
NPI 1093190118
$1,633.43
in general payments reported to CMS, 2019-2025
21 companies · $568 in 2025
The $568 reported for 2025 was more than what 85% of Neurocritical Care providers received nationally (typical 2025 total: $95.82).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $25.97 · 2021: $92.17 · 2022: $307 · 2023: $84.95 · 2024: $306 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $958.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $506.65 | 2021-2025 | Pipeline, Solitaire X, Axium Primetm |
| Penumbra, INC. | $201.68 | 2021-2022 | |
| Stryker Corporation | $165.39 | 2020-2025 | Surpass Evolve |
| Rapid Medical Ltd | $160.31 | 2024 | Tigertriever 17 Revascularization Device, Comaneci 17 |
| Boston Scientific Corporation | $94.78 | 2019 | |
| Abbott Laboratories | $89.37 | 2019 | |
| Ucb, INC. | $58.16 | 2024 | Nayzilam |
| Janssen Pharmaceuticals, INC | $54.98 | 2019 | |
| Alexion Pharmaceuticals, INC. | $43.70 | 2022 | |
| Microvention, INC. | $36.98 | 2022 | |
| Csl Behring | $31.94 | 2024 | Kcentra |
| Sk Life Science, INC. | $30.99 | 2024 | |
| Mdd US Operations, LLC | $24.38 | 2024 | Apokyn |
| Merz Pharmaceuticals, LLC | $22.29 | 2025 | Xeomin |
| Taiho Oncology, INC. | $20.95 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17.89 | 2025 | |
| Eisai INC. | $17.34 | 2025 | |
| Neurocrine Biosciences, INC. | $15.82 | 2023 | Ongentys, Ingrezza |
| Lilly USA, LLC | $14.62 | 2022 | |
| Amgen INC. | $14.04 | 2022 | |
| Genentech USA, INC. | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Saleemi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.